© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
August 14, 2021
Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.
March 26, 2021
The future of ovarian cancer treatment is discussed through a summary of current treatment options, future directions, and a review the unmet needs facing patients and physicians today.
Shannon Westin, MD, reviews essential treatment considerations for physicians when subscribing niraparib.
The utilization and effectiveness of using PARP inhibitors in treating ovarian cancer is considered.
Shannon Westin, MD, discusses niraparib and its relation to the design, efficacy, and practical implications of the PRIMA trial.
Systemic frontline therapy options are explored through the lens of treating ovarian cancer.